| 0.53505 -0.002 (-0.36%) | 12-05 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.73 | 1-year : | 0.85 |
| Resists | First : | 0.63 | Second : | 0.73 |
| Pivot price | 0.54  |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.53  |
MA(20) : | 0.56 |
| MA(100) : | 0.56 |
MA(250) : | 2.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.1 |
D(3) : | 36.9 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 8.51 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KPRX ] has closed above bottom band by 41.4%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.54 - 0.54 | 0.54 - 0.55 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.54 - 0.54 | 0.54 - 0.54 |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Thu, 09 Nov 2023
Kiora Pharmaceuticals reports Q3 results - Seeking Alpha
Thu, 09 Nov 2023
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal ... - Yahoo Finance
Fri, 01 Sep 2023
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 - Yahoo Finance
Wed, 23 Aug 2023
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of ... - Yahoo Finance
Fri, 21 Jul 2023
Why Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today? - InvestorPlace
Fri, 02 Jun 2023
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 540 (K) |
| Shares Short P.Month | 281 (K) |
| EPS | 0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.5 % |
| Return on Equity (ttm) | -136.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 0.69 |
| PEG Ratio | 0 |
| Price to Book value | 0.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|